Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Otsuka Seeks Japan Approval of Alcohol Dependence Med Nalmefene
October 18, 2017
- AZ’s Ex-Japan Chief Fredrickson Picked as Global Head of Oncology
October 18, 2017
- Durvalumab Improves PFS in Japanese NSCLC Patients
October 17, 2017
- Tagrisso Significantly Extends PFS in Japanese EGFRm NSCLC Patients
October 17, 2017
- Nobelpharma Plans to File Sakigake-Designated Topical Sirolimus; Application Expected Later this Month
October 17, 2017
- Japan’s Oncology Market Estimated to Reach Over 1.4 Trillion Yen in 2025: Fuji Keizai
October 17, 2017
- Ethical Drug Sales Up 2.2% in August, Keytruda Upbeat: Crecon
October 17, 2017
- Naldemedine Now Available in US: Shionogi
October 16, 2017
- Takeda Looks to House 3,000 Researchers at Shonan Innovation Park, Create Fund by March
October 16, 2017
- Eisai to Acquire Marketing Authorization for Kolbet from Toyama Chemical on Jan. 1
October 16, 2017
- Novartis Not to Conduct Additional Japan Study of Ribociclib, While PIb Study Underway in Asian Countries including Japan
October 16, 2017
- Sanwa Kagaku to Reduce 150 Jobs as Part of Suzuken Group’s SGA Cost Cutting Efforts
October 16, 2017
- JT Wins Japan Commercialization Rights for Calcifediol Extended-Release Capsules
October 16, 2017
- Kowa Wins Livalo Patent Suit against Towa
October 13, 2017
- Meiji Grants Carbapenem Rights to Spero Outside Japan, Asia
October 13, 2017
- Teijin Earns Japan Rights to Novel Botulinum Toxin
October 13, 2017
- Ono Grabs Rights to 2 XPO1 Inhibitors in Japan, Asia
October 13, 2017
- Daiichi Sankyo Initiates AMED-Funded Joint Research on Genetic Vaccine Platform with NIBIOHN
October 13, 2017
- LEO Pharma to Offer Cell Assays in Japan to Evaluate External Compounds under Unique Open Innovation Model
October 13, 2017
- FGF23 Antibody Burosumab Earns FDA Priority Status: Kyowa Kirin/Ultragenyx
October 12, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…